Ergotidine
Acquired Immunodeficiency
Sahlgrenska University HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Acquired Immunodeficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zinc Sulfate Fakultas Kedokteran Universitas Indonesia | Phase 4 | BB |
Cyclosporin A West China Hospital | Phase 4 | B |
Human Normal Immunoglobulin (Ivig) Takeda | Phase 3 | B |
Igpro20 CSL Behring | Phase 3 | B |
Blood Plasma Assistance Publique - Hôpitaux de Paris | Unknown | D |
Hizentra Rochester General Hospital | Phase 2/3 | NR |
Same molecule, other indications
Ergotidine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →